linkedin

Resource Library

Whitepapers

Redefining Speed In Drug Development : Samsung Biologics' S-Cellerate™ Platform


 

WHITRPAPER

Redefining Speed In Drug Development : Samsung Biologics' S-Cellerate™ Platform
Daniel Buckley
Lead Scientist in CDO Downstream

To accelerate time to market and meet urgent patient needs, we leverage all available resources in our end-to-end service, while balancing speed and quality. In this whitepaper, Daniel Buckley, our Lead Scientist in CDO Downstream, details how our proprietary technology platform, S-Cellerate, offers an expedited CDMO timeline to IND. Using S-Cellerate, clients have been able to reach IND filing in as fast as 9 months as well as access our full spectrum of services - from process characterization and validation to BLA submission - while maintaining the highest product quality and operational robustness.


 

WHITRPAPER

Redefining Speed In Drug Development : Samsung Biologics' S-Cellerate™ Platform
Daniel Buckley
Lead Scientist in CDO Downstream

To accelerate time to market and meet urgent patient needs, we leverage all available resources in our end-to-end service, while balancing speed and quality. In this whitepaper, Daniel Buckley, our Lead Scientist in CDO Downstream, details how our proprietary technology platform, S-Cellerate, offers an expedited CDMO timeline to IND. Using S-Cellerate, clients have been able to reach IND filing in as fast as 9 months as well as access our full spectrum of services - from process characterization and validation to BLA submission - while maintaining the highest product quality and operational robustness.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved